世界の感染症診断市場の規模は、2021年の281億ドルから2026年までに398億ドルに達し、CAGRは7.2％と予想されます。市場の成長を促す要因としては、感染症の世界的な蔓延とCOVID-19の発生、疾患の早期診断に対する意識の高まり、中央検査室から分散型POC検査への移行、技術の進歩などが挙げられます。
2019年12月に武漢（中国）で感染拡大が始まる前はほとんど知られていなかったCOVID-19は、わずか数週間で地域的危機から世界的な大流行へと移行しました。COVID-19のパンデミックは、ほとんどの企業の全体的な売上に悪影響を及ぼしましたが、COVID-19検査に感染症診断法を使用したため、感染症診断市場にプラスの影響を及ぼしました。COVID-19のパンデミックによるロックダウンのため人々が健康診断の受診を遅らせたことが、検査の実施件数や試薬の売上に影響を及ぼしました。 しかし、各国が徐々に移動の制限を緩和するにつれて検査数が回復してきています。
COVID-19のパンデミックによって、感染症への対応が世界的に差し迫った医学的課題になっています。 ワクチンや治療薬の開発に加えて、より正確で簡便な検査方法の開発と検査態勢の拡充がますます求められています。COVID-19は、政府や医療提供者が前例のない課題に直面しているため、規制環境や慣行にも影響を与えています。規制当局は、診断製品の承認を迅速化する方法を利用しました。企業は、COVID-19迅速検査を導入し、収益を維持し、自社の操業能力に対するCOVID-19の影響を無力化するための開発戦略を採っています。
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 30)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 34)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Key data from primary sources
2.2.2.2 Key industry insights
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
FIGURE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
FIGURE 4 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 5 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET
2.7 COVID-19 HEALTH ASSESSMENT
2.8 COVID-19 ECONOMIC ASSESSMENT
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 7 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 8 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY (Page No. - 47)
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 51)
4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
FIGURE 14 THE RISING ADOPTION OF POC DIAGNOSTICS IS EXPECTED TO SUPPORT MARKET GROWTH DURING THE FORECAST PERIOD
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 15 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET, BY PRODUCT & SERVICE, IN 2021
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 16 IMMUNODIAGNOSTICS TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026
FIGURE 17 DIAGNOSTIC LABORATORIES DOMINATE THE END-USER MARKET
5 MARKET OVERVIEW (Page No. - 54)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Global prevalence of infectious diseases and onset of COVID-19
5.2.1.2 Rising focus on R&D and funding in infectious disease diagnostics
5.2.1.3 Growing awareness for early disease diagnosis in developing countries
5.2.1.4 Rising technological advancements in infectious disease diagnostics
5.2.1.5 Shift in focus from centralized laboratories to decentralized POC testing
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in growing economies
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape
5.2.4.2 Operational barriers
5.2.5 COVID-19 IMPACT ANALYSIS
5.3 PRICING ANALYSIS
TABLE 2 PRICING ANALYSIS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021)
5.4 PATENT ANALYSIS
5.4.1 POLYMERASE CHAIN REACTION
5.4.2 IMMUNODIAGNOSTICS
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 20 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.9 PESTLE ANALYSIS
5.10 REGULATORY LANDSCAPE
5.10.1 NORTH AMERICA
5.10.1.1 US
5.10.1.2 Canada
5.10.2 EUROPE
5.10.3 ASIA PACIFIC
5.10.3.1 China
5.10.3.2 Japan
5.10.3.3 India
5.10.4 LATIN AMERICA
5.10.4.1 Brazil
5.10.4.2 Mexico
5.10.5 MIDDLE EAST
5.10.6 AFRICA
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 4 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016─2020 (USD MILLION)
TABLE 5 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016─2020 (TONS)
5.11.2 TRADE ANALYSIS FOR CULTURE MEDIA
TABLE 6 IMPORT DATA FOR CULTURE MEDIA, BY COUNTRY, 2016─2020 (USD MILLION)
TABLE 7 IMPORT DATA FOR CULTURE MEDIA, BY COUNTRY, 2016─2020 (TONS)
5.12 TECHNOLOGY ANALYSIS
5.13 YC-YCC SHIFT
FIGURE 21 YC-YCC SHIFT FOR THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 73)
6.1 INTRODUCTION
TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
6.2 REAGENTS, KITS, AND CONSUMABLES
6.2.1 REPEAT PURCHASE OF REAGENTS, KITS, AND CONSUMABLES DRIVES THE MARKET GROWTH
TABLE 9 INFECTIOUS DISEASE DIAGNOSTICS REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2019-2026 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER & ACCURATE TEST RESULTS TO PROPEL THE MARKET GROWTH
TABLE 10 KEY PRODUCTS IN THE INSTRUMENTS MARKET
TABLE 11 INFECTIOUS DISEASE DIAGNOSTICS INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTIC TESTS
TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS SOFTWARE & SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING (Page No. - 79)
7.1 INTRODUCTION
TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2019-2026 (USD MILLION)
7.2 LABORATORY TESTING
7.2.1 OUTBREAK OF COVID-19 DRIVES DEMAND FOR LAB TESTS
TABLE 14 LABORATORY TESTING MARKET, BY REGION, 2019-2026 (USD MILLION)
7.3 POC TESTING
7.3.1 THE INCREASING ADOPTION OF POC TECHNOLOGIES DRIVES THE GROWTH OF THIS SEGMENT
TABLE 15 POC TESTING MARKET, BY REGION, 2019-2026 (USD MILLION)
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 83)
8.1 INTRODUCTION
TABLE 16 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
8.2 IMMUNODIAGNOSTICS
8.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR COVID-19 DIAGNOSTICS DRIVE MARKET GROWTH
TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2019-2026 (USD MILLION)
8.3 POLYMERASE CHAIN REACTION
8.3.1 THE GROWING USE OF RT-PCR IN COVID-19 TESTS IS A MAJOR GROWTH DRIVER FOR THIS SEGMENT
TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR PCR, BY REGION, 2019-2026 (USD MILLION)
8.4 CLINICAL MICROBIOLOGY
8.4.1 GROWING ADOPTION BY RESEARCHERS AND ACADEMIA IS EXPECTED TO DRIVE MARKET GROWTH
TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2019-2026 (USD MILLION)
8.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
8.5.1 COST-BENEFITS OF INAAT DRIVE DEMAND FOR THE TECHNOLOGY
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2019-2026 (USD MILLION)
8.6 DNA SEQUENCING & NGS
8.6.1 INCREASING FOCUS ON PERSONALIZED MEDICINE IS A GROWTH DRIVER FOR THIS SEGMENT
TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2019-2026 (USD MILLION)
8.7 DNA MICROARRAYS
8.7.1 GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH
TABLE 22 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2019-2026 (USD MILLION)
8.8 OTHER TECHNOLOGIES
TABLE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2019-2026 (USD MILLION)
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE (Page No. - 92)
9.1 INTRODUCTION
TABLE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
9.2 COVID-19
9.2.1 HIGH AND GROWING CASE PREVALENCE ENSURES DEMAND FOR COVID-19 DIAGNOSTICS
TABLE 25 DISTRIBUTION OF CASES BY COUNTRY
TABLE 26 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 27 COVID-19 DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
TABLE 28 COVID-19 DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
9.3 HUMAN IMMUNODEFICIENCY VIRUS
9.3.1 THE HIGH PREVALENCE OF HIV WILL DRIVE THE MARKET GROWTH FOR THIS SEGMENT
TABLE 29 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 30 HIV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
9.4 HOSPITAL-ACQUIRED INFECTIONS
9.4.1 THE RISING BURDEN OF MRSA INFECTIONS IS A KEY FACTOR DRIVING THE MARKET GROWTH FOR THIS SEGMENT
TABLE 31 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 32 HAI DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
9.5 HEPATITIS
9.5.1 THE GLOBAL PREVALENCE OF HEPATITIS IS A KEY FACTOR DRIVING MARKET GROWTH
TABLE 33 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 34 HEPATITIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
TABLE 35 HEPATITIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
9.6 CHLAMYDIA TRACHOMATIS GENITAL INFECTIONS AND GONORRHEA
9.6.1 CT/NG INFECTIONS ARE THE MOST COMMON STDS
TABLE 36 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 37 CT/NG DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
9.7 HUMAN PAPILLOMA VIRUS
9.7.1 TECHNOLOGICAL ADVANCEMENTS SUCH AS RAPID HPV DIAGNOSTICS TO DRIVE THE MARKET GROWTH FOR THIS SEGMENT
TABLE 38 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 39 HPV DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
9.8 TUBERCULOSIS
9.8.1 THE INCREASING BURDEN OF TB GLOBALLY TO DRIVE THE MARKET GROWTH OF THIS SEGMENT
TABLE 40 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 41 TUBERCULOSIS DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
TABLE 42 TUBERCULOSIS DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
9.9 INFLUENZA
9.9.1 RISING FOCUS ON CONTAINING THE SPREAD OF INFLUENZA
TABLE 43 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
TABLE 44 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019-2026 (MILLION TESTS)
TABLE 45 INFLUENZA DIAGNOSTICS MARKET, BY METHOD, 2019-2026 (USD MILLION)
9.10 OTHER INFECTIOUS DISEASES
TABLE 46 OTHER INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER (Page No. - 104)
10.1 INTRODUCTION
TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS DRIVES MARKET GROWTH
TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019-2026 (USD MILLION)
10.3 HOSPITALS & CLINICS
10.3.1 HOSPITALS & CLINICS SHOW INCREASING ADOPTION RATE OF INFECTIOUS DISEASE DIAGNOSTIC TOOLS
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2019-2026 (USD MILLION)
10.4 ACADEMIC RESEARCH INSTITUTES
10.4.1 FOCUS ON DEVELOPING INNOVATIVE TESTS DRIVES MARKET GROWTH
TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2019-2026 (USD MILLION)
10.5 OTHER END USERS
TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019-2026 (USD MILLION)
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION (Page No. - 110)
11.1 INTRODUCTION
TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2019-2026 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 22 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
TABLE 53 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 54 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 55 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 56 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.2.1 US
11.2.1.1 US dominates the market in North America and globally
TABLE 58 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 59 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 60 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 61 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Focus on affordable tests drives the market growth
TABLE 62 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 63 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 64 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 65 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3 EUROPE
TABLE 66 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 67 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 68 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 69 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 70 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany holds the largest share of the market in Europe
TABLE 71 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 72 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 73 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 74 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.2 ITALY
11.3.2.1 Adoption of advanced diagnostic technologies to drive market growth in Italy
TABLE 75 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 76 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 77 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 78 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising R&D expenditure in France
TABLE 79 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 80 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 81 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 82 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.4 SPAIN
11.3.4.1 Healthcare infrastructural improvements indicate favorable prospects for market growth
TABLE 83 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 84 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 85 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 86 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.5 UK
11.3.5.1 The increasing number of accredited diagnostic laboratories propels market growth in the UK
TABLE 87 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 88 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 89 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 90 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 91 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 92 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 93 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 94 ROE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 23 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
TABLE 95 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
TABLE 96 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 97 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 98 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 99 APAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Growing access to modern healthcare and outbreak of COVID-19
TABLE 100 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 101 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 102 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 103 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan
TABLE 104 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 105 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 106 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 107 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth
TABLE 108 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 109 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 110 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 111 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 112 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 113 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 114 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 115 ROAPAC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE HAVE DRAWN FOREIGN PLAYERS TO LATAM MARKETS
TABLE 116 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 117 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 118 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 119 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS WILL SUPPORT MARKET GROWTH
TABLE 120 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
TABLE 121 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 122 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2026 (USD MILLION)
TABLE 123 MEA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 148)
12.1 OVERVIEW
FIGURE 24 KEY STRATEGIES IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET (2018-2021)
12.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 25 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
12.3 MARKET SHARE ANALYSIS
FIGURE 26 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020)
12.3.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET RANKING, BY DISEASE TYPE
12.3.1.1 Hepatitis
TABLE 124 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY KEY PLAYER, 2020
12.3.1.2 HIV
TABLE 125 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY KEY PLAYER, 2020
12.3.1.3 HPV
TABLE 126 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY KEY PLAYER, 2020
12.3.1.4 Influenza
TABLE 127 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY KEY PLAYER, 2020
12.3.1.5 COVID-19
TABLE 128 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY KEY PLAYER, 2020
12.4 COMPANY EVALUATION QUADRANT
12.4.1 STARS
12.4.2 EMERGING LEADERS
12.4.3 PERVASIVE PLAYERS
12.4.4 PARTICIPANTS
FIGURE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020
12.5 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)
12.5.1 PROGRESSIVE COMPANIES
12.5.2 STARTING BLOCKS
12.5.3 RESPONSIVE COMPANIES
12.5.4 DYNAMIC COMPANIES
FIGURE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2020)
12.6 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS
FIGURE 29 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET
12.7 COMPETITIVE SCENARIO
12.7.1 MARKET EVALUATION MATRIX, 2018-2020
12.7.2 INFECTIOUS DISEASE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS
TABLE 129 KEY PRODUCT LAUNCHES & APPROVALS
12.7.3 INFECTIOUS DISEASE DIAGNOSTICS: DEALS
TABLE 130 KEY DEALS
12.7.4 INFECTIOUS DISEASE DIAGNOSTICS: OTHER DEVELOPMENTS
TABLE 131 OTHER KEY DEVELOPMENTS
13 COMPANY PROFILES (Page No. - 159)
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, right to win)*
13.1.1 ABBOTT LABORATORIES
TABLE 132 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 30 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
13.1.2 F. HOFFMANN-LA ROCHE
TABLE 133 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 31 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2020)
13.1.3 BIOMÉRIEUX SA
TABLE 134 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 32 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
13.1.4 THERMO FISHER SCIENTIFIC
TABLE 135 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
13.1.5 DANAHER CORPORATION
TABLE 136 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
13.1.6 QUIDEL CORPORATION
TABLE 137 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 35 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
13.1.7 HOLOGIC
TABLE 138 HOLOGIC: BUSINESS OVERVIEW
FIGURE 36 HOLOGIC: COMPANY SNAPSHOT (2020)
13.1.8 PERKINELMER
TABLE 139 PERKINELMER: BUSINESS OVERVIEW
FIGURE 37 PERKINELMER: COMPANY SNAPSHOT (2020)
13.1.9 BECTON, DICKINSON AND COMPANY
TABLE 140 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
13.1.10 SIEMENS HEALTHINEERS AG
TABLE 141 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
13.1.11 DIASORIN S.P.A
TABLE 142 DIASORIN S.P.A: BUSINESS OVERVIEW
FIGURE 40 DIASORIN S.P.A: COMPANY SNAPSHOT (2020)
13.1.12 BIO-RAD LABORATORIES
TABLE 143 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 41 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
13.1.13 QIAGEN
TABLE 144 QIAGEN: BUSINESS OVERVIEW
FIGURE 42 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
13.1.14 GRIFOLS S.A.
TABLE 145 GRIFOLS S.A.: BUSINESS OVERVIEW
FIGURE 43 GRIFOLS S.A.: COMPANY SNAPSHOT (2020)
13.1.15 ORTHO CLINICAL DIAGNOSTICS
TABLE 146 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW
FIGURE 44 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020)
13.1.16 SYSMEX CORPORATION
TABLE 147 SYSMEX CORPORATION: BUSINESS OVERVIEW
FIGURE 45 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
13.2 OTHER PLAYERS
13.2.1 LUMINEX CORPORATION
13.2.2 MERIDIAN BIOSCIENCE
13.2.3 TRINITY BIOTECH
13.2.4 CHEMBIO DIAGNOSTIC SYSTEMS
13.2.5 ORASURE TECHNOLOGIES
13.2.6 SEEGENE
13.2.7 CO-DIAGNOSTICS
13.2.8 GENETIC SIGNATURES
13.2.9 EPITOPE DIAGNOSTICS
13.2.10 TRIVITRON HEALTHCARE
13.2.11 ELITECHGROUP
13.2.12 MERIL LIFESCIENCES PVT. LTD.
13.2.13 INBIOS INTERNATIONAL
13.2.14 ABACUS DIAGNOSTICA OY
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, right to win might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 256)
14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS
